Climb Bio to Present at Key Healthcare Investor Conferences in September 2025
Table of Contents
Climb Bio, Inc., a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases, announced its participation in two prominent investor conferences in September 2025. The company will be presenting at the Morgan Stanley Global Healthcare Conference and the Stifel Virtual Immunology and Inflammation Forum, offering opportunities for investors to learn more about its pipeline, including budoprutug and CLYM116. Live webcasts of presentations will be available on the Climb Bio website, with replays archived for at least 30 days.
Conference Details
Here’s a breakdown of the conference schedule:
Morgan Stanley Annual Global healthcare Conference:
Date: Wednesday, September 10, 2025
Time: 4:20 PM ET
Location: New York, NY
Format: One-on-one meetings only
Stifel Virtual Immunology and Inflammation Forum:
Date: Wednesday, September 10, 2025
Time: 10:30 AM ET
Location: Virtual
Format: Presentation and one-on-one investor meetings
Investors can access the live webcasts and subsequent replays through the “Investors and News” section of the Climb Bio website: https://www.climbbio.com/
about Climb Bio’s pipeline
Climb Bio is developing a pipeline of therapeutics targeting immune-mediated diseases. Their lead candidates include:
Budoprutug: An anti-CD19 monoclonal antibody designed to deplete B-cells. B-cell depletion holds therapeutic potential for a wide range of B-cell mediated diseases,such as autoimmune disorders and certain cancers. https://www.climbbio.com/pipeline
CLYM116: An anti-APRIL monoclonal antibody currently undergoing IND-enabling studies for the treatment of IgA nephropathy,a chronic kidney disease. https://www.climbbio.com/pipeline
Key Takeaways
Climb Bio will be presenting at two key investor conferences in September 2025.
The company is focused on developing therapies for immune-mediated diseases.
Budoprutug and CLYM116 are the company’s lead pipeline candidates.
Conference presentations and replays will be available on the Climb Bio website.
Investor Contact
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
Looking Ahead
Climb Bio’s participation in thes conferences underscores its commitment to transparency and engagement with the investment community. As the company progresses its clinical programs, notably CLYM116 through IND-enabling studies, these events will provide valuable platforms to share updates and discuss the potential of its innovative therapies. investors and stakeholders are encouraged to visit the Climb Bio website for further facts and to access the conference webcasts.
Related reading